Getnet Yimer

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations

Eliford Ngaimisi, Abiy Habtewold, Omary Minzi et al. · PLoS ONE · 2013 · 124 citations · Full text

Veterinary Medicine, Pharmacokinetics, Pharmacology +17

High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study

Getnet Yimer, Wondwossen Amogne, Abiy Habtewold et al. · The Pharmacogenomics Journal · 2011 · 123 citations

Pharmacy, Infectious Diseases, Pharmacokinetics +17

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients

Getnet Yimer, Nobuhisa Ueda, Abiy Habtewold et al. · PLoS ONE · 2011 · 123 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Keratin‐18 and micro <scp>RNA</scp> ‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts

Petra Thulin, Gunnar Nordahl, Marcus Gry et al. · Liver International · 2013 · 118 citations

Medicine, Pharmacology, Gene Expression +16

Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial

Sayoki Mfinanga, Bruce Kirenga, Duncan Chanda et al. · The Lancet Infectious Diseases · 2014 · 103 citations

Public Health, Infectious Disease Control, Pharmacotherapy +15